What's Changing in Your Programme Capital Story
Your next €50M of capital. The burn-to-readout forecast you sign. The thesis your specialist-fund anchor can recite back. Three questions that look separate, but are actually one. A briefing for CFOs at mid-market European biotech firms.
Thursday morning, board pack due next Thursday
Every CFO at a mid-sized European biotech has had the same Thursday morning. Four things on the screen at 8:30. Your lead programme is eighteen months from pivotal Phase 3 readout and the CMC tech-transfer timeline landed three weeks late. Your CSO wants €50M next quarter to accelerate a parallel Phase 2 asset because an AI-accelerated competitor is entering the same indication nine months ahead of plan. Your Head of BD forwarded a mid-stage in-licensing opportunity yesterday at 40% below 2021 comparables because specialist-fund distributions hit decade lows. And your specialist-fund anchor's analyst closed last week's quarterly call with a single line: curious to hear your thinking on portfolio priorities and capital discipline before JPM.
You have signed fifteen forecasts for this board. The pattern used to be simple. Advance the lead. Hold cash to the next readout. Refresh the risk-adjusted NPV once a year when the competitive picture updates. Close the quarter clean. Keep the auditor happy. The business was understandable.
Something changed. Your programme-portfolio rNPV math is under pressure as AI-accelerated competitor timelines enter the indications you have been building against for three years. Your capital is running through CSO-committee governance without ROIC discipline against in-licensing alternatives at current specialist-fund-distribution-low valuations. Your Controllers are closing faster than they ever have, and the audit committee is asking about traceability on agent-assisted programme-cost attribution. The close is clean. The portfolio story underneath it is not.
The job has not changed in thirty years. The bar has risen on every measure of doing it, simultaneously, and the portfolio contradictions you have been navigating since you took the seat are suddenly re-openable. The CFOs who treat them as engineering problems run the offensive play. The ones who treat them as permanent trade-offs lose capital-allocation authority to the CSO within eighteen months.
This briefing covers what is happening in your sector, what it means for the finance function you run, and the three questions your team should answer before the next board pack.
Mid-market biotech just lost the timeline that priced a decade of programmes
Every AI capability your competitors deploy into target identification, molecular simulation, and translational modelling compresses their programme front-third. Your risk-adjusted NPVs were built against 2019 competitor timelines that the AI-compressed reality has now made obsolete. The first AI-accelerated competitor Phase 2 readouts started landing in 2025 and 2026. As of December 2025, no AI-discovered drug has received FDA approval, so the point is not the approval date. The point is the timeline advantage in development. When a competitor entering the same indication shows several months of programme-timeline advantage at Phase 2, your lead asset's probability-adjusted NPV compresses against the plan the board voted on. The board does not read that as a scientific setback. It reads as a capital-allocation problem the finance seat has to re-open.
Your peers are not waiting. Specialty pharma and commercial-stage biotechs are treating the 2026 BD window as the buying moment of the decade. Specialist-fund distributions sit at decade lows. Mid-stage asset valuations are 30 to 50 percent below 2021 peaks. Firms with disciplined capital and clean portfolio-IRR math are in-licensing de-risked Phase 2 assets at multiples the 2021 market would not have honoured. Others are renegotiating milestone and royalty architectures built on 2019 timeline assumptions that no longer hold. A smaller set of the more patient ones are building the programme-portfolio intelligence that specialist-fund investors cannot see elsewhere. They are the quiet compounders. The rest of the sector is running programme budgets on spreadsheets built when AI-compressed competition was theoretical.
Your programme rNPV is compressing. Your capital-allocation process still runs on 2019 timeline assumptions. The science is doing its job. The portfolio decision is one the finance seat has not yet claimed.
The sector is repricing underneath everyone at the same time. The EU Omnibus lifted 80 percent of companies out of direct CSRD scope in February 2026, splitting firms into those redeploying their development-data foundation into programme-portfolio intelligence and those deflating the investment. EU HTA Joint Clinical Assessments went live for oncology and ATMPs in 2025 and expand to Class IIb and III medical devices in 2026. The mid-market sits where these shifts converge, and the firms treating them as separate compliance projects rather than one data architecture are walking into a JPM conversation they will not win.
Your capital, your forecast, and your narrative are feeling it every day
Your capital allocation. Your CSO's €50M acceleration request is running through the same programme-committee governance you use for protocol amendments. It is not a programme-timeline request. It is the largest single capital-allocation decision you will make this decade, and it deserves the same discipline you bring to BD. The finance seats that ship this as a capital-line decision to the board, with alternatives analysis against in-licensing a de-risked Phase 2 asset, CDMO capacity build, and hold-to-next-readout, keep the authorship for the next ten years. The ones that sign the revised programme budget hand the authorship to the CSO by default.
Your forecast. The annual plan was built on Phase 3 readout timing and probability-of-success assumptions from 2024 competitive intelligence. The competitor entering your best indication is now running on an AI-compressed Phase 2 schedule several months ahead of your model. Your Head of FP&A cannot reconstruct the portfolio-level story because programme-cost attribution lives in clinical-operations spreadsheets, development-stage probabilities sit in the CSO's head, CDMO cost overruns sit in the Head of Technical Operations' email, and regulatory timeline risk sits in the Head of Regulatory's briefing notes. The forecast was not aggressive. The data architecture underneath it was built for annual reconciliation rather than continuous reconstruction of the portfolio story.
Your royalty and milestone architecture. The royalty stack on your inbound and outbound licensing deals was structured against 2019 timeline assumptions. Milestones triggered on dates AI-compressed competitors now beat. The deal architecture that ran clean from 2018 to 2023 is now the reason your lead asset's economic returns compress faster than your programme advances. Royalty architecture is a capital-allocation question about where the returns get captured, not a BD housekeeping task. Your treasury is bringing you the royalty-stack question in the same breath as the first-cycle BLA acceptance question, and neither lives in a clean model.
Your controller and FP&A bench. The journal entries, programme-cost attribution drafting, milestone-revenue-recognition checks, R&D credit claim preparation, and first-draft board-pack generation that used to train a junior controller into a Senior Controller into a VP Finance are now running on agents. The Q1 headcount win is real. The 2031 succession bench is empty. The finance function that cuts the junior layer without rebuilding the entry pathway has a cheaper quarter this year and no internal CFO candidate in five.
Your economic thesis. Your board has asked for the strategy-day preview. Your specialist-fund anchor has asked for a portfolio-prioritisation note before JPM. Your chair has asked how the firm stays ahead of AI-accelerated competitive timelines. Three audiences, three different documents, each drafted by a different team. None of them are anchored in the same data. The CFOs pulling ahead write the thesis once and let the three audiences draw from the same architecture. The ones behind them are editing three decks and hoping the probability assumptions match.
You do not have three scorecard problems. You have one.
Your sector is repricing from the front of the pipeline because AI-accelerated competitors bring compressed Phase 2 timelines into the indications you have been building against for three years. Your finance function is stretched because the forecast credibility, the capital-allocation authority, and the economic thesis are each being managed as a separate programme, each drawing on a different data layer, each drafted by a different team. Same force, two altitudes. But there is a third thing happening that most mid-market biotech CFOs have not named yet, and it is the one that matters most.
Capital allocation without forecast credibility is guessing. Forecast credibility without a narrative is scorekeeping. A narrative without a data architecture underneath it is marketing. The finance seat that holds all three holds one integrated asset, not three separate programmes. Every capital-allocation question, every forecast-credibility gap, every narrative weakness is a symptom of the same missing layer: the programme-capital-intelligence infrastructure that feeds all three from the same data, the same governance, the same discipline.
This is the ERP decision of this decade. Every biotech CFO in your cohort is making it right now, whether they see it or not. The ones who personally owned the 1993 to 1998 ERP decision kept capital-allocation authority for the next twenty years. The ones who signed the IT requisition because "that was an IT decision" watched the CIO take a board seat and the next CFO hire come from outside. The shape is the same. The asset under decision is different. The cost of getting it wrong in 2026 is compressed into eighteen months instead of five years.
You can tell which camp a firm is in from a single question. Can your team answer any material board question by walking the same portfolio graph, in the same meeting, with the same data? Most mid-market biotechs cannot. The ones that can have already made the shift, and they are the ones specialist-fund investors are already rewarding.
You have twelve to eighteen months. The 2026-2027 BD window is a short cycle. The CFOs who own this decision personally run the offensive play. The ones who do not become the CFO the board replaces when the successor walks in with a thesis.
What most firms are doing. What the winners are doing instead.
Every biotech CFO has had the AI conversation. Most are making the same four decisions. A smaller group is making different ones.
| The default path | The winners' path |
|---|---|
| Run the CSO's programme budget as the capital planSign the revised burn. CSO committee owns the allocation. BD window passes while the acceleration debate runs. | Route programme capital through the BD hurdleFive options on one page: accelerate, in-license, CDMO build, commercial prep, hold runway. ROIC discipline against each. |
| Hold milestone architecture from 2019 assumptionsRoyalties trigger on dates AI-compressed competitors now beat. Value capture erodes as programmes advance. | Renegotiate royalty and milestone architectureMilestones re-indexed against AI-compressed competitor timelines. Value capture holds when programmes advance on faster clocks. |
| Run the portfolio on annual probability refreshTwelve-month cadence. Ten scenarios take a quarter. Competitor timeline shifts surface in post-mortem. | Rebuild the forecast as a live portfolio graphTen scenarios in an afternoon. Competitor timeline shifts surface in the same board meeting, not next quarter. |
| Cut the controller layer for the Q1 winHeadcount down fifteen to twenty-five percent. Empty succession bench in 2031. External CFO hire the year after. | Redesign the junior pathway around judgmentNew hires pair with agents on portfolio scenarios, BD diligence, governance. Bench rebuilds faster than it would have grown. |
The default path shows a cleaner Q1. The winners' path has visible friction for three quarters and compounds from month fifteen. The difference is whether the CFO is authoring the capital or administering it.
Capital Allocation. Forecast Credibility. Value-Creation Narrative.
Three questions every biotech CFO is tracking. The first is the crux. The other two are how you earn the right to answer it.
Where does the next €50M actually compound?
Lead-programme acceleration? In-licensing a de-risked Phase 2 asset at specialist-fund-distribution-low valuations? CDMO capacity build for the near-commercial asset? Commercial launch infrastructure? Hold runway to the next readout? Today's default: the CSO proposes, the programme committee governs, the revised budget gets signed, and the capital-allocation authority slides away from the seat. The question is not which programme. The question is whose decision this is.
Why is the portfolio rNPV compressing, and what is the programme-level story?
Your board voted on a 2028 launch and a risk-adjusted NPV anchored in 2024 competitive intelligence. Your Head of FP&A cannot walk the audit committee through the portfolio-level story because programme costs sit in clinical-ops spreadsheets, development-stage probabilities sit in the CSO's head, and regulatory timeline risk sits in the Head of Regulatory's email. Ten programme scenarios used to take a quarter. They now run in an afternoon. The bar has risen on what credible means.
What does this firm do that compounds faster than peers?
Your board wants the strategy-day preview. Your specialist-fund anchor wants the portfolio-prioritisation note. Your chair wants the how-we-stay-ahead-of-AI-accelerated-competitors answer. Three audiences, three documents, three teams, and the probability assumptions underneath them do not match. The CFOs pulling ahead write the thesis once and refresh it continuously from the same data architecture that runs the forecast. The three audiences read excerpts of the same document.
What the firms winning this play are actually doing
Four concrete moves any biotech CFO can start this quarter. Each addresses one lever. Pulled together, they become one programme-capital-intelligence asset the firm runs on.
Capital: route programme acceleration through the BD hurdle, not the programme committee
Your CSO's €50M request is a capital-allocation decision. Treat it like one. Present the alternatives on one page: lead-programme acceleration, in-licensing a de-risked Phase 2 asset, CDMO capacity build, commercial launch prep, hold runway to next readout. ROIC-scored against the same horizon you use for BD. Name what you are choosing not to fund to protect the thing you are funding. That is the sentence that keeps authorship at the seat.
Forecast: rebuild the portfolio as a live probability-adjusted graph, not an annual refresh
Your programme-portfolio rNPV model should draw from live competitor-timeline intelligence, live regulatory-pathway risk, live CMC cost attribution, and live commercial launch-readiness data as one graph rather than five spreadsheets stitched together. Ten scenarios compress from a quarter to an afternoon. Competitor timeline shifts produce the portfolio-level story in the same board meeting, not in the post-mortem.
Milestones and royalties: renegotiate the architecture against AI-compressed timelines
Your inbound and outbound deal architecture was structured against 2019 competitor-timeline assumptions. AI-compressed competition changes what milestone-triggered value capture looks like in practice. Re-index the royalty stack and milestone schedule against current competitor Phase 2 and Phase 3 timelines. The 2026 BD window is a short cycle and mid-stage asset valuations are 30 to 50 percent below 2021 peaks. Finance authors the renegotiation plan. BD executes against it.
Narrative: write the economic thesis once, refresh continuously
Three sentences on one page. What does this firm do that compounds faster than peers when AI-accelerated competitors enter your best indications? What capital gets starved to protect it? What gets fed? Refresh the thesis continuously off the same portfolio graph that runs the forecast. Specialist-fund pre-JPM note excerpts the thesis. Audit-committee prep excerpts the thesis. Strategy-day deck excerpts the thesis. Three audiences, one artefact, four registers. The CFO authors the narrative. The board recites it back.
The only firm joining capital authorship to working agents
The biotech CFO has four places to go. None can do what we do.
The big life-sciences transformation practices sell twelve-to-twenty-four-month programmes staffed by partners and analysts billing hours. Their audit arm constrains their governance advice. Their billable-day model requires selling substrate that agents commoditise. They ship a tighter close, not authorship of the portfolio.
The specialty biotech strategy boutiques sell quarterly-cadence diagnostics. They write the portfolio-prioritisation thesis as a deck. They cannot put a working rNPV agent in the CFO's hands in three weeks.
The life-sciences portfolio-management vendors sell software licences and a long implementation. Your moat has to sit on firm-owned infrastructure, or it becomes a vendor asset at renegotiation.
The specialist-fund IR advisors sell narrative polish tuned to analyst relationships. None can run the capital-allocation-plus-portfolio-intelligence conversation the seat requires.
The market offers four things you have already said no to. GRAIL is the fifth option.
- Senior advisory that speaks board-room, not deck-room
- Working infrastructure your team uses the same week
- Custom agents built on your portfolio, your book, your data
- The start of a programme-intelligence layer your FP&A owns
- No vendor lock-in at any phase of the engagement
- Founded by operators who have carried CFO-adjacent seats
- Business first, technology second
- Three weeks from first meeting to working infrastructure
- Your team keeps the infrastructure, you own the IP
- Every next step earned by what just shipped, never assumed
Three sessions with your finance leadership. Working infrastructure from week one.
We start with your finance leadership team because the change cannot outrun the team's personal understanding of what is possible. Three workshops. Each delivers standalone value. Each earns the right to the next.
How to think
Walk through what is happening in your sector and inside your finance function. Build the first piece of infrastructure in the room: a live portfolio-rNPV agent on your real programme model, running against your real competitor-timeline, CMC, and regulatory-pathway data. Your leadership team leaves with a shared view of what to do next and the first piece of working infrastructure already in their hands.
Your finance infrastructure
A half-day build. Your Controller, Head of FP&A, Treasurer, Head of BD, and Head of IR each leave with five to ten pieces of working infrastructure tuned to their function. Programme-cost attribution agents. Continuous portfolio scenarios. Royalty-stack intelligence. BD diligence acceleration. Board-pack narrative drafting. Infrastructure your team is using the same week, not decks about infrastructure.
Ready to run
Refined infrastructure based on real use. The rollout plan to the wider finance organisation. The capital-allocation-thesis document for the next board meeting. The milestone-renegotiation roadmap for BD. And the CEO and specialist-fund conversation with numbers they can check: ROIC alternatives, portfolio scenarios, moat measurement.
Three weeks. No IT project. No board approval needed to start. The infrastructure your finance function is already running on when we finish.
For your next forecast review
The questions where your finance leadership cannot agree are the ones worth an hour on the agenda.
Your CSO wants €50M to accelerate a parallel Phase 2 asset. Is it in the programme-committee budget as a timeline request, or on the capital page as one option among five?
Your board voted on a risk-adjusted NPV anchored in 2024 competitive intelligence. Can your team walk the audit committee through the portfolio-level story against AI-accelerated competitor timelines in the same meeting, or does it take a post-mortem?
Your royalty-stack and milestone architecture was set against 2019 competitor-timeline assumptions. What is the twelve-month plan to renegotiate the architecture, and who on your team is authoring it?
Your specialist-fund anchor, your chair, and your CEO have each asked for a different portfolio document in the last ninety days. Are they excerpting the same thesis, or are your teams drafting three that do not reconcile?
Of the junior controllers and FP&A analysts you are cutting to agents this year, how many would have made your 2031 succession bench? What are you doing instead to build that bench?
If any of these produces a disagreement in your finance leadership, that is the conversation worth having before the board asks.
Continue reading
Sources and limitations
This briefing draws on GRAIL's engagement experience with leadership teams and on public company disclosures. Figures are illustrative unless a source is named beside them. A sourced edition is in preparation.